Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding.
Oxidative stress, with reactive oxygen intermediate formation, may represent a common mechanism by which liver injury is induced by diverse etiologies. Oxidative stress enhances nuclear factor kappa B (NF-kappa B) activity, and NF-kappa B activity has been shown to enhance the expression of cytotoxic cytokines. Acute hepatic injury caused by reactive oxygen intermediate production was induced by an intraperitoneal injection of CCl4 in mice. This injury was significantly inhibited by intravenous pretreatment of the mice with a water-soluble emulsion of alpha-tocopherol. Alpha-tocopherol treatment of the mice given the CCl4 also reduced the NF-kappa B binding to levels approaching those found in normal mice. In vitro treatment of a monocyte/macrophage cell line with CCl4 led to enhanced NF-kappa B binding and an increase in tumor necrosis factor-alpha (TNF-alpha) messenger RNA levels. Liver specimens taken from patients with acute fulminant hepatitis had markedly increased NF-kappa B binding activity in comparison with the binding of normal livers. These data demonstrate that abolishing acute hepatic injury with alpha-tocopherol, a free radical scavenger, also eliminated increased NF-kappa B binding. It is tempting to speculate that enhanced NF-kappa B expression caused by free radical production/oxidative stress may modulate liver injury, perhaps through an effect on cytotoxic cytokine synthesis.
Liu
S L
SL
Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA.
Degli Esposti
S
S
Yao
T
T
Diehl
A M
AM
Zern
M A
MA
D000818:Animals; D002251:Carbon Tetrachloride / Q000633:toxicity*; D002460:Cell Line; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D006801:Humans; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D009000:Monocytes / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism*; D009336:Necrosis / Q000139:chemically induced / Q000517:prevention & control; D018384:Oxidative Stress; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D014810:Vitamin E / Q000627:therapeutic use*
D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D014810:Vitamin E; D002251:Carbon Tetrachloride